Attenuation of experimental autoimmune demyelination in complement-deficient mice

被引:106
作者
Nataf, S
Carroll, SL
Wetsel, RA
Szalai, AJ
Barnum, SR
机构
[1] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA
[4] Univ Texas, Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA
关键词
D O I
10.4049/jimmunol.165.10.5867
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The exact mechanisms leading to CNS inflammation and myelin destruction in multiple sclerosis and in its animal model, experimental allergic encephalomyelitis (EAE) remain equivocal. In both multiple sclerosis and EAE, complement activation is thought to play a pivotal role by recruiting inflammatory cells, increasing myelin phagocytosis by macrophages, and exerting direct cytotoxic effects through the deposition of the membrane attack complex on oligodendrocytes, Despite this assumption, attempts to evaluate complement's contribution to autoimmune demyelination in vivo have been limited by the lack of nontoxic and/or nonimmunogenic complement inhibitors. In this report, we used mice deficient in either C3 or factor B to clarify the role of the complement system in an Ah-independent model of EAE, Both types of complement-deficient mice presented with a markedly reduced disease severity, Although induction of EAE led to inflammatory changes in the meninges and perivascular spaces of both wild-type and complement-deficient animals, in both C3(-/-) and factor B-/- mice there was little infiltration of the parenchyma by macrophages and T cells. In addition, compared with their wild-type littermates, the CNS of both C3(-/-) and factor B-/- mice induced for EAE are protected from demyelination, These results suggest that complement might be a target for the therapeutic treatment of inflammatory demyelinating diseases of the CNS.
引用
收藏
页码:5867 / 5873
页数:7
相关论文
共 52 条
  • [1] TYPE-1 ASTROCYTES AND OLIGODENDROCYTE-TYPE-2 ASTROCYTE GLIAL PROGENITORS MIGRATE TOWARD DISTINCT MOLECULES
    ARMSTRONG, RC
    HARVATH, L
    DUBOISDALCQ, ME
    [J]. JOURNAL OF NEUROSCIENCE RESEARCH, 1990, 27 (03) : 400 - 407
  • [2] Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease
    Barnum, SR
    [J]. MOLECULAR MEDICINE, 1999, 5 (09) : 569 - 582
  • [3] Myelin oligodendrocyte glycoprotein: A novel candidate autoantigen in multiple sclerosis
    Bernard, CCA
    Johns, TG
    Slavin, A
    Ichikawa, M
    Ewing, C
    Liu, J
    Bettadapura, J
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 1997, 75 (02): : 77 - 88
  • [4] TNF-ALPHA SUPPRESSES CR3-MEDIATED MYELIN REMOVAL BY MACROPHAGES
    BRUCK, W
    BRUCK, Y
    FRIEDE, RL
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 1992, 38 (1-2) : 9 - 17
  • [5] The role of complement and complement receptors in induction and regulation of immunity
    Carroll, MC
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 : 545 - 568
  • [6] Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA
    Circolo, A
    Garnier, G
    Fukuda, W
    Wang, XF
    Hidvegi, T
    Szalai, AJ
    Briles, DE
    Volanakis, JE
    Wetsel, RA
    Colten, HR
    [J]. IMMUNOPHARMACOLOGY, 1999, 42 (1-3): : 135 - 149
  • [7] IMMUNOCYTOCHEMICAL LOCALIZATION OF THE TERMINAL COMPLEMENT COMPLEX IN MULTIPLE-SCLEROSIS
    COMPSTON, DAS
    MORGAN, BP
    CAMPBELL, AK
    WILKINS, P
    COLE, G
    THOMAS, ND
    JASANI, B
    [J]. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1989, 15 (04) : 307 - 316
  • [8] CROSS AH, 1990, LAB INVEST, V63, P162
  • [9] Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement
    Czermak, BJ
    Lentsch, AB
    Bless, NM
    Schmal, H
    Friedl, HP
    Ward, PA
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (05) : 1513 - 1524
  • [10] Czermak BJ, 1999, J IMMUNOL, V162, P2321